Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie funkcjonalnym rezonansem magnetycznym kontroli hamowania w chorobie afektywnej dwubiegunowej i dużej depresji (COLIBRI)

12 listopada 2026 zaktualizowane przez: CHU de Reims

Neurofunkcjonalna Charakterystyka Kontroli Hamowania w Chorobie Afektywnej Dwubiegunowej i Dużej Depresji

Bipolar disorder and unipolar depressive disorder are two chronic mood disorders associated with a significant social impact, even during euthymic phases. Their differential diagnosis remains complex, particularly when bipolar disorder begins with a depressive episode. Identifying distinctive markers between these pathologies therefore represents a major clinical and economic challenge, as appropriate mood-stabilizing treatment can reduce healthcare costs and improve patients' functional outcomes.

Among potential biomarkers, executive functions-and more specifically inhibition-have received particular attention. Inhibitory deficits are observed in both disorders, including during euthymic states, and also among first-degree relatives, suggesting their potential as cognitive and cerebral endophenotypes. These deficits may help explain the difficulties in emotion regulation and impulsivity frequently observed in mood disorders.

Two components of inhibition are distinguished:

  1. Behavioral inhibition, which refers to the ability to stop an ongoing response.
  2. Interference control, which refers to the ability to resist distraction. These processes rely on partially distinct neural networks and operate at different stages of information processing. The few studies comparing these two components in bipolar disorder have shown contradictory results, and neuroimaging investigations have only partially explored these mechanisms, particularly their emotional dimension. It is, however, well established that patients with bipolar or depressive disorders show greater difficulties in executive tasks involving emotional stimuli than in purely cognitive tasks.

The study is expected to reveal:

  • Differences in brain activation between euthymic bipolar and unipolar depressive patients in regions involved in inhibitory control, modulated by the emotional content of the task.
  • Distinct cognitive performance profiles according to pathology, reflecting specific alterations in inhibitory and interference processes.

These findings should provide a better understanding of the differential neurocognitive bases of mood disorders. Identifying specific cognitive and neural profiles could contribute to more accurate differential diagnosis and to the personalization of therapeutic interventions, particularly through cognitive remediation strategies targeting executive and emotional deficits.

Przegląd badań

Szczegółowy opis

Bipolar disorder (BD) and unipolar depressive disorder (UDD) are chronic mood disorders that cause significant functional and social impairment, even during euthymic phases. The differential diagnosis between these two conditions remains challenging, especially when bipolar disorder initially manifests with a depressive episode, the most frequent onset pattern. Identifying reliable biomarkers that distinguish BD from UDD is therefore a major clinical and scientific objective. Early and appropriate introduction of mood-stabilizing treatments is associated with improved long-term outcomes and reduced healthcare costs through fewer hospitalizations.

Scientific Background and Rationale:

Executive dysfunctions, particularly inhibitory control deficits, have been consistently observed in both BD and UDD, including during remission. Similar deficits in first-degree relatives suggest that these alterations could represent cognitive or neural endophenotypes. Inhibition, defined as the ability to suppress a dominant or prepotent response, plays a central role in emotion regulation.

Inhibitory control can be divided into two complementary components:

  1. Behavioral inhibition, the ability to suppress or stop a prepotent motor response.
  2. Interference control, the ability to resist irrelevant or distracting information that interferes with ongoing cognitive processing.

Neuroimaging studies in healthy populations have revealed distinct but overlapping neural networks underlying these two processes. However, data on BD and UDD remain limited and sometimes inconsistent, particularly regarding the differential involvement of these two components and their modulation by emotional context.

Objectives:

The primary objective of this study is to investigate, using functional magnetic resonance imaging (fMRI), the brain circuits underlying the two mechanisms of inhibitory control - behavioral inhibition and interference control - in both their cognitive and emotional components, among euthymic patients with BD or UDD, compared with matched healthy controls.

Secondary objectives include:

  • Comparing cognitive performance between groups.
  • Exploring associations between cognitive performance, clinical characteristics (e.g., age at onset, number of episodes, symptom severity), and brain activation profiles.

Study Design:

This is a monocentric, prospective, cross-sectional study including four participant groups: patients with BD, patients with UDD, and their respective matched control groups. Each participant will complete three study visits:

  • Visit 1 (V1): Clinical assessment and inclusion. Participants will provide informed consent and undergo a standardized diagnostic evaluation (DSM-5 criteria), assessment of current mood symptoms, and collection of sociodemographic and clinical data.
  • Visit 2 (V2): Neuropsychological testing. A standardized battery will assess executive functions, including inhibition, interference control, cognitive flexibility, working memory, and processing speed.
  • Visit 3 (V3): MRI acquisition. Participants will undergo both structural (T1-weighted) and functional (BOLD) MRI scans while performing two experimental tasks targeting inhibitory control.

Experimental Paradigms and Imaging Procedures:

Two validated cognitive paradigms will be used:

  • Behavioral inhibition task (Stop-Signal task): assesses the ability to inhibit prepotent motor responses. Emotional and neutral stimuli will be randomly presented to explore emotional modulation of inhibitory processes.
  • Interference control task (Flanker task): assesses the ability to resist interference from cognitive or emotional distractors, isolating attentional control mechanisms.

MRI data will be acquired using a 3-Tesla scanner. Functional sequences will use gradient-echo echo-planar imaging optimized for BOLD contrast, with a temporal resolution of approximately 2 seconds and a spatial resolution of ~3 mm isotropic. High-resolution T1-weighted anatomical images (1 mm isotropic) will be acquired for normalization and morphometric analysis.

Data Analysis:

Preprocessing and statistical analyses will be performed using standard neuroimaging software. Data will undergo motion correction, spatial normalization to MNI space, and Gaussian smoothing.

First-level analyses will be conducted using a general linear model to model activation for cognitive and emotional conditions.

Second-level (group) analyses will use hierarchical mixed-effects models to identify between-group differences in neural activation patterns (BD vs. UDD vs. controls). Correlation analyses will explore relationships between brain activation, cognitive performance, and clinical variables.

Statistical significance will be set at p < 0.05 family-wise error corrected for multiple comparisons, and p < 0.001 uncorrected for exploratory analyses.

Innovation and Expected Outcomes:

This study is among the first to jointly investigate behavioral and interference components of inhibitory control in both cognitive and emotional domains in euthymic BD and UDD patients. The combination of neuropsychological and fMRI approaches will:

  • Characterize specific activation patterns underlying inhibitory control deficits.
  • Identify potential cognitive and neural endophenotypes distinguishing BD from UDD.
  • Clarify the influence of emotional context on inhibitory processing.
  • Explore correlations between clinical, cognitive, and neurofunctional data. These findings are expected to improve understanding of the differential pathophysiology of mood disorders, contribute to the development of objective diagnostic biomarkers, and guide targeted therapeutic interventions (e.g., cognitive remediation, emotion regulation strategies).

Typ studiów

Interwencyjne

Zapisy (Szacowany)

120

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Group 1 and 2: Bipolar patients, Depressive patients

Inclusion criteria:

  • Patients between 18 and 65 years old, men or women, right-handed
  • Having a diagnosis of bipolar disorder or depressive disorder
  • No substantial change in treatment for 2 weeks preceding study enrollment
  • Being a native French speaker
  • Patients enrolled in the national healthcare insurance program
  • Consenting to participate to the study

Exclusion criteria:

  • The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
  • A significant general medical illness, including neurological disorders or head trauma
  • Contraindication to the use of MRI
  • A sensorial impairment uncorrected (visual and/or hearing)

Group 3 and 4: Healthy control participants

Inclusion criteria:

  • Participants between 18 and 65 years old, men or women, right-handed
  • Being a native French speaker
  • Patients enrolled in the national healthcare insurance program
  • Consenting to participate to the study

Exclusion criteria:

  • A diagnosis of schizophrenia or of bipolar disorder or of major depressive disorder according to DSM-5 criteria
  • The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence
  • Participants having one first-degree relative presenting an bipolar disorder or depressive disorder or schizophrenia according to DSM-5 criteria
  • A significant general medical illness, including neurological disorders or head trauma
  • Contraindication to the use of MRI
  • A sensorial impairment uncorrected (visual and/or hearing)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Nielosowe
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Group 1: Bipolar patients

Patients with a diagnosis of bipolar disorder

Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams

Eksperymentalny: Group 2: Major depressive patients

Patients with a diagnosis of major depressive disorder

Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams

Aktywny komparator: Group 3: Bipolar controls

Healthy control participants matched to group 1

Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams

Aktywny komparator: Group 4: Depressive controls

Healthy control participants matched to group 2

Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
fMRI activations during an behavioral inhibition task (emotional stop signal task)
Ramy czasowe: Day 0

Participants will perform a gender discrimination task on emotional and non-emotional faces. Under Go conditions, the participant must respond. Under non-Go conditions, the frame of the image changes color and the participant must not respond. The faces express neutrality (50%) or anger (50%).

Day 0
fMRI activations during an emotional interference control (emotional Flanker task)
Ramy czasowe: Day 0

Participants were instructed to discriminate the gender of a target stimulus during an emotional Flanker task. The stimuli consist of faces expressing a neutral or angry emotion. The central face (the target) may display the same emotion (congruent condition) or a different emotion (incongruent condition) from the faces on the right and left (two flankers). Participants must say, as quickly and accurately as possible, what the gender of the central face is

Day 0

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Psychological profiles: depression
Ramy czasowe: Day 0

Evaluated through the Hamilton Depression Rating Scale (HAM-D). HAM-D is a widely used self-report scale to assess depressive symptoms consisting of 21 items, which has been validated in French. The total score is obtained by adding the scores of the 17 first items, the score ranging from 0 to 52, with higher scores indicating greater depression symptoms.

Day 0
Psychological profiles: mania
Ramy czasowe: Day 0

Evaluated through the Young Mania Rating Scale (YMRS). The YMRS is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items, the score ranging from 0 to 60 and higher scores indicating greater manic symptoms.

Day 0
Psychological profiles: anxiety symptoms
Ramy czasowe: Day 0

Anxiety severity is assessed with the Spielberger State-Trait Inventory (STAI) which is a 40-item scale, using a 4-point Likert scale for each item. This scale was used to measure both trait anxiety (how dispositionally anxious a person is across time and situations) and state anxiety (how anxious a person is feeling at a particular moment). The total score is obtained by adding items, the score ranging from 20 to 80. Higher scores indicate greater anxiety symptoms.

Day 0
Social functioning: quality of life
Ramy czasowe: Day 0

Evaluated through the World Health Organization Quality of Life (WHOQOL-BREF) quality of life assessment. The WHOQOL-BREF consists of 26 items scored in four domains: physical, psychological, social relationships, and environment. The score ranges from 0 to 100 with the higher score indicating a better quality of life.

Day 0
Executive functions: verbal inhibition performance
Ramy czasowe: Day 0

Evaluated through the Hayling Sentence Completion Test. The HCST consists of two sets of 15 sentences each having the last word missing. In the first section the examiner reads each sentence aloud and the participant has to simply complete the sentences, yielding a simple measure of response initiation speed. The second part of the Hayling requires participants to complete a sentence with a nonsense ending word (and suppress a sensible one), giving measures of response suppression ability and thinking time. The number of correct answers and the total time are recorded for each part. The higher the number of correct answers, the better the performance. The longer the response time, the lower the performance. For each part, the score ranges from 0 to 15.

Day 0

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

3 listopada 2026

Zakończenie podstawowe (Szacowany)

1 listopada 2029

Ukończenie studiów (Szacowany)

1 stycznia 2030

Daty rejestracji na studia

Pierwszy przesłany

11 marca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

25 marca 2026

Pierwszy wysłany (Rzeczywisty)

31 marca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj